Orthocell granted Chinese patent on Celgro

Company News

Regenerative medicine company Orthocell Limited (ASX:OCC) has been granted a patent in China for its Celgro collagen technology.
Shares in the company pushed more than 2 per cent higher yesterday on the news.
The company says the patent covers the manufacture of biological materials to repair damaged soft tissue.
Managing Director Paul Anderson says this further strengthens the company’s global intellectual property position for its unique regeneratice therapies.
He says this comes at a time when the company is moving its products through international registration processes.
Orthocell reported a net loss of $2.18 million in the 2014 financial year.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.